Note 9 - Intangible Assets
|12 Months Ended|
Mar. 31, 2020
|Notes to Financial Statements|
|Intangible Assets Disclosure [Text Block]||
2009and again in
2012,the Corporation entered into agreements with Neptune Wellness Solutions Inc. (
Neptune) pursuant to which the Corporation obtained a license and exercised its option under this license agreement to pay in advance all of the future royalties payable to Neptune. This license allows the Corporation to exploit the intellectual property rights in order to develop novel active pharmaceutical ingredients into commercial products for the prescription drugs market. The license agreement, together with the Corporation-owned intellectual property, allows the “freedom to operate” for CaPre, which is currently the Corporation’s only prescription drug candidate in development. The Corporation believes that upon the expiry of the last licensed Neptune patent in
2022,the Corporation’s expanding patent portfolio will cover CaPre, and that it will
notrequire any licenses to support the commercialization of CaPre.
Amortization expense on intangible assets for the years ended
March 31, 2020and
$1,949,respectively, and have been included in research and development expenses.
The entire disclosure for all or part of the information related to intangible assets.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef